title: New-generation therapy for ANCA-associated vasculitis.
abstract: Newer therapies for systemic vasculitis are required to improve the efficacy and reduce the toxicity associated with current agents. Our understanding of its pathogenesis is increasing with the availability of targeted therapies. B-cell depletion with rituximab is now a licensed therapy for ANCA vasculitis. Targets for therapy currently in development in ANCA associated vasculitis include blockade of complement and pro-inflammatory cytokines, and inhibition of T cell co-stimulation.
authors.affiliation: Department of Medicine, University of Cambridge, Cambridge, CB22QQ, UK. dj106@cam.ac.uk.
authors.forename: David
authors.initials: D
authors.lastname: Jayne
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D000069283:Rituximab; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D016207:Cytokines; D007166:Immunosuppressive Agents; D018836:Inflammation Mediators; D000069283:Rituximab